NYSE:AORTMedical Equipment
Assessing Artivion (AORT) Valuation After Trial Successes And Upcoming Earnings Catalysts
Why Artivion’s latest trial data and upcoming earnings matter now
Artivion (AORT) has drawn fresh attention after releasing one and two year clinical results from its NEXUS TRIOMPHE and AMDS PERSEVERE aortic repair trials, just as investors look ahead to this week’s earnings update.
See our latest analysis for Artivion.
At a share price of $40.34, Artivion has seen short term pressure, with a 30 day share price return of 9.04% and a 90 day share price return of 15.31%. Its 1 year total...